Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT00376675 · ClinicalTrials.gov registry record · Phase 3

Methylphenidate in Treating Patients With Fatigue Caused by Cancer

A Phase 3 study of Unspecified Adult Solid Tumor, Protocol Specific and Fatigue, sponsored by Alliance for Clinical Trials in Oncology.

Completed
Registry status
Phase 3
Development phase
148
Enrollment target
20
Study locations

NCT00376675 is a Phase 3 study of Unspecified Adult Solid Tumor, Protocol Specific and Fatigue that has completed, run by Alliance for Clinical Trials in Oncology. The registered enrollment target is 148 participants, below the 499-participant average among 83 other Unspecified Adult Solid Tumor, Protocol Specific trials with a reported enrollment target (70% lower). The trial reports 20 study locations across 3 states.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT00376675, a Phase 3 study of Unspecified Adult Solid Tumor, Protocol Specific and Fatigue, has completed, sponsored by Alliance for Clinical Trials in Oncology.

COMPLETED
Registry status
Phase 3
Development phase
148 participants
Enrollment target
20
Study locations

Study Summary

RATIONALE: Methylphenidate may help relieve fatigue caused by cancer. It is not yet known whether methylphenidate is more effective than a placebo in relieving fatigue and improving quality of life in patients with cancer. PURPOSE: This randomized phase III trial is studying methylphenidate to see how well it works in treating patients with fatigue caused by cancer.

Interventions

  • OTHER placebo
  • DRUG methylphenidate hydrochloride

Study Locations (20)

Colorado

  • Aurora Presbyterian Hospital - Aurora
  • Boulder Community Hospital - Boulder
  • Penrose Cancer Center at Penrose Hospital - Colorado Springs
  • St. Anthony Central Hospital - Denver
  • Porter Adventist Hospital - Denver
  • Presbyterian - St. Luke's Medical Center - Denver
  • St. Joseph Hospital - Denver
  • Rose Medical Center - Denver
  • CCOP - Colorado Cancer Research Program - Denver
  • Swedish Medical Center - Englewood
  • St. Mary's Regional Cancer Center at St. Mary's Hospital and Medical Center - Grand Junction
  • North Colorado Medical Center - Greeley
  • Sky Ridge Medical Center - Lone Tree
  • Hope Cancer Care Center at Longmont United Hospital - Longmont
  • McKee Medical Center - Loveland
  • St. Mary - Corwin Regional Medical Center - Pueblo
  • North Suburban Medical Center - Thornton
  • Exempla Lutheran Medical Center - Wheat Ridge

Arizona

  • Mayo Clinic Scottsdale - Scottsdale

Florida

  • Mayo Clinic - Jacksonville - Jacksonville

Trial Details

FieldValue
Enrollment Target 148 participants
Start Date 2008-02
Est. Completion 2010-06
Phase Phase 3

What the Registry Record Tells You About NCT00376675

The ClinicalTrials.gov registry entry for NCT00376675 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 148 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 499-participant average among 83 other Unspecified Adult Solid Tumor, Protocol Specific trials with a reported enrollment target (70% lower). The listed sponsor is Alliance for Clinical Trials in Oncology, which has 446 total studies on file at ClinicalTrials.gov.

The record links to 2 conditions, with Unspecified Adult Solid Tumor, Protocol Specific appearing as the primary indexed condition, and to 2 interventions - of which placebo is the first listed.

NCT00376675 reports 20 study locations spanning 3 distinct geographic areas - top geographies include Colorado, Arizona, Florida.

Frequently Asked Questions

What is clinical trial NCT00376675 about?

NCT00376675 is a clinical study titled "Methylphenidate in Treating Patients With Fatigue Caused by Cancer". RATIONALE: Methylphenidate may help relieve fatigue caused by cancer. It is not yet known whether methylphenidate is more effective than a placebo in relieving fatigue and improving quality of life in patients with cancer. PURPOSE: This randomized phase III trial is studying methylphenidate to see ...

What is the current status of trial NCT00376675?

This trial is currently completed. It is a Phase 3 study. The enrollment target is 148 participants. The study started on 2008-02. Estimated completion is 2010-06.

What conditions does trial NCT00376675 study?

This clinical trial studies the following conditions: Unspecified Adult Solid Tumor, Protocol Specific, Fatigue.

What interventions are being tested in trial NCT00376675?

The interventions under investigation include: placebo (OTHER), methylphenidate hydrochloride (DRUG).

Who is sponsoring clinical trial NCT00376675?

This trial is sponsored by Alliance for Clinical Trials in Oncology, which has 446 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT00376675 being conducted?

This trial has 20 study locations across Arizona, Colorado, Florida. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Unspecified Adult Solid Tumor, Protocol Specific

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.